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Abstract This study used data from the California Can-
cer Registry to comprehensively examine ﬁrst primary
central nervous system tumors (PCNST) by the Interna-
tional Classiﬁcation of Childhood Cancers (ICCC)
diagnostic groups and to compare their incidence by age
groups, sex, race/ethnicity, socioeconomic status and tumor
behavior. The study period, 2001–2005, represents the ﬁrst
5 years of benign PCNST data collection in the state. The
age-adjusted incidence rates were 2.1 for malignant and 1.3
for benign per 100,000. Children younger than 5 years old
had the highest incidence of malignant PCNST (2.6 per
100,000). Teens aged 15–19 had the highest incidence of
benign PCNST (1.8 per 100,000). Age-speciﬁc incidence
rates were nearly the same for Hispanics, non-Hispanic
whites, and Asian/Paciﬁc Islanders for malignant PCNST
among children younger than 5 (2.6–2.7 per 100,000); non-
Hispanic whites had the highest rates in the 5–14 year-old
age group (2.5 per 100,000) and Asian/Paciﬁc Islanders the
highest among the 15–19 year old age group (2.3 per
100,000). We found no statistically signiﬁcant differences
in the incidence of malignant PCNST by race/ethnicity in
any age group. Astrocytoma had the highest incidence for
both malignant and benign histology in most age groups.
Keywords Brain and other central nervous system
neoplasms  Epidemiology  Cancer incidence 
Childhood cancers  Ethnic groups
Introduction
Primary tumors of the central nervous system (PCNST)
among children, adolescents, and teens differ from those
in adults in frequency, histological appearance, and clini-
cal behavior [1]. PCNST are the second most common
form of cancer among children aged 15 years and younger
and the third most common among those 15–19 years old
in California. While PCNST represent only 1.3% of inci-
dent cancers among adults 20 years and older, they
represent from 26.4% (5–9 year olds) to 9.5% (15–19 year
olds) of incident cancers among persons younger than
20 years old [2]. PCNST are the second leading cause of
cancer deaths among children younger than 15 years old;
they cause 32% (5–9 year olds) and 12.1% (15–19 year
olds) of cancer deaths in children compared to 3% of
cancer deaths for adults 20 years and older [2]. PCNST
among children, adolescents, and teens tend to have short
latent periods, often grow rapidly, and are aggressively
invasive [1]. PCNST are a signiﬁcant public health prob-
lem, they have a far more devastating effect on society,
M. Brown (&)  K. Bauer
Public Health Institute/California Department of Public Health,
Chronic Disease Surveillance and Research Branch, 1825 Bell
Street, Suite 102, Sacramento, CA 95825, USA
e-mail: MBrown@ccr.ca.gov; MonBrown@ucdavis.edu
K. Bauer
e-mail: KBauer@ccr.ca.gov
M. Brown
Division of Hematology and Oncology, Department of Internal
Medicine, University of California at Davis, 4860 Y Street, Suite
3740, Sacramento, CA 95817, USA
R. Schrot
Department of Neurological Surgery, University of California at
Davis, 4860 Y Street, Suite 3740, Sacramento, CA 95817, USA
e-mail: Rudolph.Schrot@ucdmc.ucdavis.edu
J. Dodge
Public Health Institute, Fresno, 1320 East Shaw Avenue,
Suite 160, Fresno, CA 93710, USA
e-mail: JDodge@phifresno.org
123
J Neurooncol (2009) 94:263–273
DOI 10.1007/s11060-009-9860-1communities and considering the potential years of pro-
ductive life lost [3].
This study examined the incidence of malignant and
benign ﬁrst PCNST among children, adolescents, and teens
using the population-based California Cancer Registry
(CCR) from 2001 to 2005. This population is a subset of the
population described in the authors’ companion publication
inthisedition.Since1988,Californiastatelawmandatesthe
reporting of all newly diagnosed malignant cancers in Cal-
ifornia [4]. An amendment to this law enacted January 2001
provides for the additional reporting of benign and border-
line behavior PCNST [5]. The 2001–2005 study period
represents the ﬁrst 5 years of complete PCNST data col-
lection in California. The CCR provides a robust source of
epidemiologic data for a densely populous geographic area.
California can be viewed as a microcosm of United States
reﬂecting the inﬂuence of its racial, ethnic and sociodemo-
graphic diversity on overall cancer incidence. Although
pediatric PCNST incidence has been relatively well studied,
this is the ﬁrst study to comprehensively examine PCNST
incidence by patient demographics and tumor behavior
among children, adolescents and teens according to the
International Classiﬁcation of Childhood Cancers (ICCC).
Materials and methods
Materials and methods, including case identiﬁcation,
inclusion/exclusion criteria and tumor behavior assignment
used in this study were identical to those described in the
authors’ companion publication in this edition. For these
analyses, we divided cases into 4 age groups. Patients
younger than 5 and patients 5–9 years old are referred to as
children, those aged 10–14 years as adolescents, and those
15–19 years old as teens. Diagnostic groups were orga-
nized using the Surveillance, Epidemiology and End
Results (SEER) Program’s site/histology modiﬁcation to
the ICCC [6, 7]. Table 1 lists ICCC diagnostic groups by
Table 1 SEER recode of ICCC diagnostic groups and ICD-O-3 codes for California cases, 2001–2005
Diagnostic groups ICD-O-3 code(s)
Morphology Topography
IIIA Ependymomas & choroid
plexus tumor
9383, 9390–9394, 9390 C000–C809
IIIB Astrocytomas 9380 C723
9384, 9400, 9401, 9410, 9411, 9420, 9421,
9423, 9424, 9440–9442
C000–C809
IIIC1 Medulloblastomas 9470–9472, 9474, 9480 C000–C809
IIIC2 Primitive neuroectodermal
tumors (PNET)
9473 C000–C809
IIIC9 Other intracranial &
intraspinal embryonal
tumors
9501–9503 C700–C729
9508 C000–C809
IIID Other gliomas 9380 C700–C722, C724–
C729, C751, C753
9381, 9382, 9430, 9450, 9451, 9460 C000–C809
IIIE Other speciﬁed intracranial &
intraspinal neoplasms
8270–8281, 8300, 9350–9352, 9360–9362, 9412, 9413,
9492, 9493, 9505–9507, 9530–9537, 9537–9539
C000–C809
XA Intracranial & intraspinal
germ cell tumors
9060, 9064, 9065, 9070–9072, 9080–9085, 9100 C700–C729,
C751–C753
Z Other 8000–8005, 9370 C700–C729,
C751–C753
9501–9503 C000–C699,
C739–C768, C809
8680, 8728, 8810, 8850, 8920, 9120, 9121, 9130, 9150, 9161,
9260, 9490, 9500, 9522, 9523, 9540–9571, 9590, 9591, 9650, 9670,
9671, 9675, 9680, 9684, 9687, 9690, 9691, 9695, 9698, 9699, 9702, 9705,
9714, 9719, 9727–9729, 9731, 9733, 9734, 9740, 9741, 9750
C000–C809
SEER Surveillance, Epidemiology and End Results
ICCC International Classiﬁcation of Childhood Cancers, 3rd edition
ICD International Classiﬁcation of Diseases, Oncology, 3rd edition
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tion’s (ICD-O-3) morphology and topography codes.
Results
There were 2,096 cases of PCNST among children, ado-
lescents, and teens (from birth to 19 years old) in
California from 2001 to 2005. Of those cases, 1,114
(53.1%) were malignant, 698 (33.3%) were benign, and
284 (13.6%) were of uncertain behavior. The resultant
AAIR per 100,000 was 2.1 (CI: 2.0–2.2) for malignant, 1.3
(CI: 1.2–1.4) for benign, and 0.5 (CI: 0.5–0.6) for tumors of
uncertain behavior.
As seen in Table 2, there was an increase in the pro-
portion of cases by year for tumors of uncertain behavior
for adolescents and teens, whereas the proportion of cases
among the two groups of children, for both malignant and
benign PCNST, appears to be stable over the study period.
The ASIR for malignant PCNST decreased as age
increased, starting from 2.6 per 100,000 among those
younger than 5 years to 1.7 per 100,000 among 15 to 19-
year olds. To compare with other studies, we calculated the
AAIR per 100,000 for children and adolescents to be 2.2
for malignant and 1.2 for benign PCNST. The ASIR for
benign PCNST ﬂuctuated by age groups, ranging from 1.8
to 1.1 per 100,000. The incidence of tumors of uncertain
behavior was very low. The pattern seen for malignant
PCNST by age group was opposite that for tumors of
uncertain behavior. Incident rates increased slightly as age
group increased.
The highest incidence of PCNST was for malignant
tumors in children and adolescents (Fig. 1). This pattern
changed for teens, where incidence of benign PCNST was
similar to that of malignant PCNST. The lowest incidence,
at every age group, was for tumors of uncertain behavior.
The ASIR for boys for malignant and uncertain behavior
PCNST were higher than that for girls at all age groups.
Incidence rates for girls with benign PCNST were higher
than that for boys until adolescence, where they appeared
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Fig. 1 Age-speciﬁc incidence rates (ASIR) of ﬁrst primary malignant
and benign ﬁrst primary central nervous system tumors by age group
and sex, California, 2001–2005
Table 2 Number of cases, percent and age-speciﬁc incidence rate* (ASIR) of ﬁrst primary central nervous system tumors by age group, tumor
behavior and year of diagnosis, California, 2001–2005
Age group Behavior 2001 2002 2003 2004 2005 Total
n % n % n % n % n % n % ASIR 95%CI
\5 years Malignant 65 19.2 73 21.5 67 19.8 58 17.1 76 22.4 339 100.0 2.6 (2.4, 2.9)
Benign 34 22.1 29 18.8 34 22.1 33 21.4 24 15.6 154 100.0 1.2 (1.0, 1.4)
Uncertain 11 20.4 14 25.9 7 13.0 11 20.4 11 20.4 54 100.0 0.4 (0.3, 0.5)
Total 110 20.1 116 21.2 108 19.7 102 18.6 111 20.3 547 100.0 4.2 (3.9, 4.6)
5–9 years Malignant 70 23.6 59 19.9 61 20.5 53 17.8 54 18.2 297 100.0 2.3 (2.0, 2.5)
Benign 28 18.9 30 20.3 37 25.0 30 20.3 23 15.5 148 100.0 1.1 (1.0, 1.3)
Uncertain 7 10.8 13 20.0 15 23.1 14 21.5 16 24.6 65 100.0 0.5 (0.4, 0.6)
Total 105 20.6 102 20.0 113 22.2 97 19.0 93 18.2 510 100.0 3.9 (3.6, 4.3)
10–14 years Malignant 49 19.2 60 23.5 46 18.0 53 20.8 47 18.4 255 100.0 1.9 (1.6, 2.1)
Benign 23 14.4 34 21.3 33 20.6 29 18.1 41 25.6 160 100.0 1.2 (1.0, 1.4)
Uncertain 15 19.7 11 14.5 14 18.4 12 15.8 24 31.6 76 100.0 0.6 (0.4, 0.7)
Total 87 17.7 105 21.4 93 18.9 94 19.1 112 22.8 491 100.0 3.6 (3.3, 3.9)
15–19 years Malignant 37 16.6 45 20.2 34 15.2 60 26.9 47 21.1 223 100.0 1.7 (1.5, 2.0)
Benign 41 17.4 46 19.5 45 19.1 50 21.2 54 22.9 236 100.0 1.8 (1.6, 2.1)
Uncertain 14 15.7 17 19.1 18 20.2 20 22.5 20 22.5 89 100.0 0.7 (0.6, 0.8)
Total 92 16.8 108 19.7 97 17.7 130 23.7 121 22.1 548 100.0 4.2 (3.9, 4.6)
* Age-speciﬁc incidence rates are per 100,000 population. Rates are standardized to the 2000 US population
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123to be same; later ASIRs increased among teen girls, where
they exceed the malignant PCNST rate in boys. Adoles-
cents showed the widest sex-speciﬁc gulf for malignant
PCNST. The ASIR among girls starts to decline
dramatically from 5 to 14 years old; incidence rates for
boys declined as well but not as dramatically. When
PCNST incidence rates were compared by age group, sex,
and tumor behavior, we found that there were no signiﬁcant
Table 3 Number of cases and
percent of ﬁrst primary central
nervous system tumors, by age
group, population demographic
characteristics and tumor
behavior, California, 2001–2005
Shaded cells categories with
less than 5 cases were omitted
n% n % n% n%
% 9 . 3 5 5 9 2 % 6 . 5 5 0 3 % 8 . 6 4 2 7 % 9 . 6 5 3 9 1 e l a M x e S
% 1 . 6 4 2 5 2 % 4 . 4 4 4 2 % 2 . 3 5 2 8 % 1 . 3 4 6 4 1 e l a m e F
Race/ethnicity Non-Hispanic white 108 31.9% 62 40.3% 23 42.6% 193 35.3%
% 9 . 5 2 3 % 2 . 5 8 % 2 . 6 1 2 k c a l b   c i n a p s i H - n o N
% 9 . 7 4 2 6 2 % 3 . 6 4 5 2 % 8 . 4 4 9 6 % 6 . 9 4 8 6 1 c i n a p s i H
% 1 . 9 0 5 % 1 . 7 1 1 % 9 . 0 1 7 3 r e d n a l s I   c i f i c a P - n a i s A
% 8 . 1 0 1 % 5 . 1 5 n w o n k n U / r e h t O
% 0 . 5 4 6 4 2 % 0 . 0 5 7 2 % 8 . 6 4 2 7 % 4 . 3 4 7 4 1 w o L
% 8 . 8 1 3 0 1 % 2 . 2 2 2 1 % 8 . 8 1 9 2 % 3 . 8 1 2 6 m u i d e M
% 2 . 6 3 8 9 1 % 8 . 7 2 5 1 % 4 . 4 3 3 5 % 3 . 8 3 0 3 1 h g i H
% 9 . 4 9 9 1 5 % 6 . 2 9 0 5 % 5 . 3 9 4 4 1 % 9 . 5 9 5 2 3 n a b r U
% 1 . 5 8 2 % 5 . 6 0 1 % 1 . 4 4 1 l a r u R
Total 339 154 54 547
% 4 . 1 5 2 6 2 % 0 . 0 6 9 3 % 9 . 5 4 8 6 % 2 . 2 5 5 5 1 e l a M x e S
% 6 . 8 4 8 4 2 % 0 . 0 4 6 2 % 1 . 4 5 0 8 % 8 . 7 4 2 4 1 e l a m e F
Race/ethnicity Non-Hispanic white 113 38.0% 74 50.0% 25 38.5% 212 41.6%
% 5 . 5 8 2 % 1 . 6 9 % 7 . 5 7 1 k c a l b   c i n a p s i H - n o N
% 7 . 3 4 3 2 2 % 2 . 6 4 0 3 % 2 . 7 3 5 5 % 5 . 6 4 8 3 1 c i n a p s i H
Asian-Pacific Islander 24 8.1% 8 5.4% 8 12.3% 40 7.8%
% 3 . 1 7 % 0 . 0 0 % 7 . 1 5 n w o n k n U / r e h t O
% 5 . 2 4 7 1 2 % 7 . 7 4 1 3 % 1 . 5 3 2 5 % 1 . 5 4 4 3 1 w o L
% 2 . 9 1 8 9 % 9 . 6 1 1 1 % 0 . 3 2 4 3 % 8 . 7 1 3 5 m u i d e M
% 2 . 8 3 5 9 1 % 4 . 5 3 3 2 % 9 . 1 4 2 6 % 0 . 7 3 0 1 1 h g i H
% 5 . 4 9 2 8 4 % 8 . 3 9 1 6 % 2 . 3 9 8 3 1 % 3 . 5 9 3 8 2 n a b r U
% 5 . 5 8 2 % 8 . 6 0 1 % 7 . 4 4 1 l a r u R
Total 297 148 65 510
% 8 . 6 5 9 7 2 % 6 . 6 5 3 4 % 3 . 1 5 2 8 % 4 . 0 6 4 5 1 e l a M x e S
% 2 . 3 4 2 1 2 % 4 . 3 4 3 3 % 8 . 8 4 8 7 % 6 . 9 3 1 0 1 e l a m e F
Race/ethnicity Non-Hispanic white 113 44.3% 78 48.8% 33 43.4% 224 45.6%
Non-Hispanic black 10 3.9% 10 6.3% 8 10.5% 28 5.7%
% 9 . 9 3 6 9 1 % 8 . 0 4 1 3 % 1 . 8 3 1 6 % 8 . 0 4 4 0 1 c i n a p s i H
% 5 . 7 7 3 % 8 . 3 6 % 6 . 0 1 7 2 r e d n a l s I   c i f i c a P - n a i s A
% 2 . 1 6 % 0 . 0 0 % 1 . 3 5 n w o n k n U / r e h t O
% 5 . 0 4 9 9 1 % 7 . 8 4 7 3 % 3 . 6 3 8 5 % 8 . 0 4 4 0 1 w o L
% 7 . 7 1 7 8 % 2 . 3 1 0 1 % 9 . 1 2 5 3 % 5 . 6 1 2 4 m u i d e M
% 8 . 1 4 5 0 2 % 2 . 8 3 9 2 % 9 . 1 4 7 6 % 7 . 2 4 9 0 1 h g i H
% 7 . 5 8 2 % 8 . 0 9 9 6 % 4 . 4 9 1 5 1 % 3 . 5 9 3 4 2 n a b r U
% 3 . 4 9 3 6 4 % 2 . 9 7 % 6 . 5 9 % 7 . 4 2 1 l a r u R
Total 255 160 76 491
% 1 . 3 5 1 9 2 % 4 . 8 5 2 5 % 8 . 2 4 1 0 1 % 9 . 1 6 8 3 1 e l a M x e S
% 9 . 6 4 7 5 2 % 6 . 1 4 7 3 % 2 . 7 5 5 3 1 % 1 . 8 3 5 8 e l a m e F
Race/ethnicity Non-Hispanic white 102 45.7% 105 44.5% 40 44.9% 247 45.1%
Non-Hispanic black 12 5.4% 9 3.8% 7 7.9% 28 5.1%
% 7 . 8 3 2 1 2 % 4 . 0 4 6 3 % 6 . 3 4 3 0 1 % 7 . 2 3 3 7 c i n a p s i H
Asian-Pacific Islander 35 15.7% 17 7.2% 5 5.6% 57 10.4%
Other/Unknown
% 5 . 0 4 2 2 2 % 0 . 6 3 2 3 % 5 . 4 4 5 0 1 % 1 . 8 3 5 8 w o L
% 5 . 9 1 7 0 1 % 0 . 8 1 6 1 % 8 . 0 2 9 4 % 8 . 8 1 2 4 m u i d e M
% 0 . 0 4 9 1 2 % 1 . 6 4 1 4 % 7 . 4 3 2 8 % 0 . 3 4 6 9 h g i H
% 2 . 3 9 1 1 5 % 0 . 1 9 1 8 % 5 . 4 9 3 2 2 % 8 . 2 9 7 0 2 n a b r U
% 8 . 6 7 3 % 0 . 9 8 % 5 . 5 3 1 % 2 . 7 6 1 l a r u R
Total 223 236 89 548
Level of 
Urbanization
< 5 
years
5-9
years
10-14
years
15-19
years
Socioeconomic
Status
Level of 
Urbanization
Socioeconomic
Status
Socioeconomic
Status
Level of 
Urbanization
Level of 
Urbanization
Socioeconomic
Status
Total Uncertain Malignant Benign Demographic Characteristics
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123differences except among adolescents. The ASIR for
malignant PCNST for adolescent boys was 2.2 (CI: 1.9–
2.6) and for adolescent girls was 1.5 (CI: 1.2–1.8).
Malignant PCNST incidence among teen boys and girls
was 2.1 (CI: 1.7–2.5) and 1.4 (CI: 1.1–1.7), respectively.
Benign PCNST among teen boys and girls was 1.5 (CI:
1.2–1.8) and 2.2 (CI: 1.8–2.6), respectively.
Table 3 shows the study population by age groups,
demographic characteristics, and tumor behavior. For
nearly all age groups, boys were more often diagnosed with
malignant PCNST and tumors of uncertain behavior; girls,
proportionally, had more benign PCNST. The exception
was for adolescents, where boys were proportionally
diagnosed more often with benign PCNST.
Hispanic children, younger than 5, had proportionally
more PCNST. Non-Hispanic white adolescents and teens
had proportionally more PCNST. In the 5–9 age group,
Hispanic children had more malignant and uncertain
behavior PCNST while non-Hispanic white children had
more benign PCNST.
Among children younger than 5, more cases were from
lower socioeconomic status (SES) regardless of tumor
behavior. For children 5–9, more cases of malignant and
uncertain PCNST were in low SES, while benign cases
were from high SES. For adolescents and teens, all cases of
malignant PCNST were from high SES. For adolescents,
more benign cases were from high SES while uncertain
cases were from low SES. For teens, the opposite was
seen—more uncertain cases were from high SES while
more benign cases were from low SES. Lastly, over-
whelmingly, more cases, regardless of tumor behavior were
from urban areas of California than from rural.
Incidence rates were calculated for race/ethnic groups
by tumor behavior in Table 4. For many subgroups by age,
race/ethnicity, or tumor behavior, incidence rates could not
be calculated due to the small number of cases. Where
incidence rates could be calculated and compared, we
found no statistically signiﬁcant differences by race/eth-
nicity for any age group by tumor behavior. Incidence rates
for all tumor behaviors were highest in non-Hispanic white
children aged 5–9 years and in adolescents with the
exception of malignant tumors, which were highest in
Asian/Paciﬁc Islander children younger than 5 and teens.
At every age group, astrocytomas (IIIB), ependymomas,
and choroid plexus (IIIA) predominated (Table 5). For
both malignant and benign PCNST, at nearly every age
group, astrocytoma had the highest incidence. Among
children younger than 5 years old, the primary malignant
diagnoses were ependymomas and choroid plexus (IIIA),
while for children 5–9 years old, other gliomas (IIID) was
Table 4 Age-speciﬁc incidence
rate
a (ASIR) with 95%
conﬁdence interval (CI) of ﬁrst
primary central nervous system
tumors by age group, tumor
behavior and race/ethnicity,
California, 2001–2005
a Age-speciﬁc incidence rates
are per 100,000 population.
Rates are standardized to the
2000 US population
Shaded cells rates could not be
calculated if number of cases
were less than 15 and/or the
underlying population was less
than 100,000
Age Group Race
ASIR 95%CI ASIR 95%CI
< 5 years Non-Hispanic White 2.6 (2.2, 3.2) 1.5 (1.2, 1.9)
Non-Hispanic Black 2.3 (1.4, 3.5)
Hispanic 2.6 (2.2, 3.0) 1.1 (0.8, 1.4)
Asian-Pacific Islander 2.7 (1.9, 3.8)
Total 2.6 (2.4, 2.9) 1.2 (1.0, 1.4)
5-9 years Non-Hispanic White 2.5 (2.1, 3.1) 1.7 (1.3, 2.1)
Non-Hispanic Black 1.7 (1.0, 2.8)
Hispanic 2.2 (1.9, 2.6) 0.9 (0.7, 1.2)
Asian-Pacific Islander 1.8 (1.1, 2.6)
Total 2.3 (2.0, 2.5) 1.1 (1.0, 1.3)
10-14 years Non-Hispanic White 2.3 (1.9, 2.7) 1.6 (1.2, 1.9)
Non-Hispanic Black
Hispanic 1.7 (1.4, 2.1) 1.0 (0.8, 1.3)
Asian-Pacific Islander 1.8 (1.2, 2.7)
Total 1.9 (1.6, 2.1) 1.2 (1.0, 1.4)
15-19 years Non-Hispanic White 2.0 (1.6, 2.5) 2.1 (1.7, 2.5)
Non-Hispanic Black
Hispanic 1.4 (1.1, 1.8) 2.0 (1.6, 2.4)
Asian-Pacific Islander 2.3 (1.6, 3.2) 1.1 (0.7, 1.8)
Total 1.7 (1.5, 2.0) 1.8 (1.6, 2.1)
Malignant Benign
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123ranked ﬁrst only slightly ahead of astrocytomas (IIIB),
which was followed closely by medulloblastomas (IIIC1).
For adolescents, germ cell tumors (XA) ranked a close
second to astrocytomas (IIIB). Among teens, benign
PCNST classiﬁed as other speciﬁed intracranial and intra-
spinal tumors (IIIE) were ranked ﬁrst; the majority of
patients in that sub-category were diagnosed speciﬁcally
with pituitary adenoma (66.7%). Overall, pituitary ade-
noma comprised 20.1% of all diagnoses in teens. In all age
groups, the majority of tumors of uncertain behavior were
classiﬁed as other speciﬁed intracranial and intraspinal
tumors (IIIE) classiﬁcation. In nearly every age group, the
majority of those patients were diagnosed speciﬁcally with
gangliogliomas, representing between 37.0% (5–9 year
olds) and 47.8% (10–14 year olds) of those cases. Among
children younger than 5 years old, nearly an equal number
of patients were diagnosed with craniophargiomas and
gangliogliomas (36.1 and 38.9%, respectively).
Table 6 shows the distribution of astrocytomas; both
malignant and benign numbered nearly the same for boys
and girls younger than 15 years old, while among teens,
they predominated in boys. Further, boys had the most
ependymomas and choroid plexis tumors, medulloblasto-
mas, and PNET. Although astrocytomas and PNET tumors
were distributed nearly equally among non-Hispanic white
and Hispanic children; all other histologies were more
frequently seen in adolescent and teen non-Hispanic
whites. In the low SES group, ependymomas and choroid
plexis tumors, medulloblastomas, and PNET were found
most often among children younger than 10 years old.
Astrocytomas were found mostly among low SES children
younger than 5, with a near even distribution among those
5–9 and among high SES adolescents and teens. Further-
more, benign astrocytomas were found mainly in the low
SES group for children younger than 5 and in teens. In high
SES groups however astrocytoma were found mainly
among those 5–14 years old.
Discussion
This is the ﬁrst study to examine both malignant and
benign PCNST among children, adolescents, and teens in
California. Fifty-three percent of PCNST among those
younger than 20 years old were malignant, 33.3% benign,
and the remainder was of uncertain behavior. The AAIR of
malignant PCNST in this age group was 2.1 cases per
100,000 persons and for benign PCNST, 1.3 per 100,000.
Among children and adolescents younger than 15 years
old, the malignant PCNST was 2.2 per 100,000 and for
benign PCNST, 1.2 per 100,000.
In the present study, the incidence of malignant tumors
decreased with increasing age. The highest incidence for
malignant PCNST was found among children younger than
5 years old [8–11], whereas teens had the highest incidence
of benign and uncertain behavior PCNST. Post-mortem
studies on younger brains have found a higher relative
concentration of neural stem cells [12, 13], which suggests
that the immature brain might possess an increased
capacity to generate malignant neuroepithelial tumors
through increased populations of neural stem and progen-
itor cell types, supporting the stem cell hypothesis for
tumor formation [14].
Consistent with results found for adults, boys at every
age group had a higher incidence of malignant tumors,
while girls generally had a higher incidence of benign
tumors [11, 15]. Signiﬁcant sex-speciﬁc differences were
not found for malignant PCNST in the 5–9 year age group
or for benign PCNST among adolescents. The incidence of
malignant PCNST in girls dropped sharply starting in the
5–9 year old age group while the incidence of benign
PCNST rose just as dramatically starting in the adoles-
cence. Age- and sex-speciﬁc tumor frequency and tumor
behavior transition are postulated to be hormone-related,
coinciding with the onset of puberty, although the speciﬁc
mechanism has yet to be determined [16]. For example, in
a case report, the growth and regression of a pilocytic
astrocytoma was found to be related to exogenous human
growth hormone (hGH) [17].
In our study, astrocytomas were the prominent diagno-
ses for malignant PCNST in most age groups, which is
consistent with other national and international studies [8,
10, 11, 15, 18–29]. Ependymomas and choroid plexus
tumors were highest among children younger than 5 years
old [19, 20, 26, 27], while other gliomas and medullo-
blastomas had a similar incidence to astrocytomas in the 5–
9 age group [11, 20]. We noted a surge in germ cell tumors
for adolescents, which declined for teens concurrent with
an increase in pituitary tumors [16, 30, 31]. The propor-
tional incidence of pituitary adenomas in our study
population was similar to that reported by CBTRUS,
although our methods varied [21].
California’s unique race/ethnic population allows anal-
yses of the distribution of cancer incidence in groups that
might otherwise be overlooked or inaccurately counted.
California’s younger population (\20 years old) is pre-
dominantly Hispanic (45.8%). Hispanics represent 50.2%
of children younger than 5 years old, 47.8% of those in the
5–9 age group, and 44.3% of the adolescent group. How-
ever, in the teen group, the Hispanic population is nearly
equal to the non-Hispanic white population (40.9 and
39.5%, respectively) [32]. Therefore not surprisingly, in
our study the highest proportional incidence of malignant
PCNST was among Hispanic children younger than
10 years old; non-Hispanic whites had the highest inci-
dence among 10–19 year olds. The ASIR reported for
J Neurooncol (2009) 94:263–273 269
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123malignant PCNST for children younger than 5 (2.6–2.7 per
100,000) was nearly the same for Hispanics, non-Hispanic
whites, and Asian/Paciﬁc Islanders. Non-Hispanic whites
had the highest incidence among 5–14 year olds (2.5 per
100,000) and Asian/Paciﬁc Islanders had the highest inci-
dence among teens (2.3 per 100,000). The differences in
these incidence rates were not statistically signiﬁcant.
This is the ﬁrst study to examine the proportions of
PCNST incidence by SES in this age group. We found that
children younger than 10 years old in the lowest SES group
had a higher proportional incidence of malignant PCNST,
while children and adolescents 5–19 years old in the
highest SES group had a higher incidence of benign
PCNST compared to other SES groups. This ﬁnding may
be related to unique class level exposures or indirectly
related to race/ethnicity population distribution, speciﬁ-
cally those groups that are more likely at the lower SES
levels and/or differential healthcare coverage [33]. Cancer
incidence has been found to be highest among those with
more education, greater income, and with private insurance
[34, 35]. Reasons for this are unclear. Some have advanced
the theory, least in childhood leukemia, that higher SES
groups are immunologically shielded by hyperhygienic
environments, leading to naı ¨ve immune systems which are
more prone to cancer development [36, 37].
Common causes for differences in CNS tumor incidence
statistics between epidemiologic studies were discussed at
length in the authors’ companion publication in this edition.
Unique to comparisons of pediatric CNS tumor incidence
statistics is the variation in the selection of age groupings
across sources and the use of the ICCC. The ICCC was
designed speciﬁcally for childhood cancers and is based on
tumor morphology in conjunction with primary anatomical
site, rather than histology and anatomical site separately as
is common [6, 7]. Additionally, SEER created a recode
system for the ICCC [6, 7], as it did for the ICD-O [38]. The
ICCC SEER site recode is used by the CCR, all North
American central cancer registries, NPCR and SEER to
organize histologies but not by CBTRUS or in international
studies. Even when the ICCC was used, valid comparisons
between studies and statistical sources could not be made
because many of those studies used cases from a single
institution or if population-based, did not calculate inci-
dence rates [39–41]. When rates were available, the detail
necessary for valid comparison was not the same [18, 42].
We found the use of the ICCC to have limitations. Although
appropriate for showing transitioning tumor occurrence by
age groups, the ICCC was inadequate for delineating
PCNST among teens. For example, 20% of benign PCNST
among teens were pituitary adenomas, which were other-
wise hidden in the category of ‘‘other intracranial and
intraspinal’’, since they are nearly nonexistent among
children and adolescents younger than 15 years old.
Our study’s strengths and weakness have been discussed
in the authors’ companion publication in this edition.
Speciﬁc to this study, even though 5 years of benign data
had been collected, due to the small numbers of cases,
stable and accurate incidence rates could not be calculated
for many sex-race/ethnic-age group combinations among
children, adolescents, and teens.
Primary central nervous system tumors are a major
source of cancer morbidity and mortality among children,
adolescents, and teens. While PCNST incidence has been
relatively well-researched, this is the ﬁrst study to com-
prehensively examine benign PCNST by ICCC diagnostic
groups and age groups, and to compare them to malignant
PCNST. In addition, this is one of the few studies to
examine PCNST among adolescents [22, 24, 30, 43]. This
study of California PCNST among children, adolescents,
and teens provides a basis for future basic, translational and
clinical brain tumor research and for both healthcare and
public health in California.
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